Risk estimation of venous thromboembolism and thrombosis prophylaxis in relation to pregnancy;Beslut om trombosprofylax vid graviditet - Enklare med riskpoäng

Lakartidningen

Volumn 103, Issue 18, 2006, Pages 1429-1432

  Lindqvist, Pelle G ^a   Hellgren, Margareta ^b,c   Nord, Eva ^d   Nyman, Margareta ^e  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c Karolinska Universitetssjukhuset Solna ^*

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e DANDERYD HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ARTICLE; BANDAGE; DECISION MAKING; FEMALE; HUMAN; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY COMPLICATION; PUERPERAL DISORDER; RISK ASSESSMENT; RISK FACTOR; VEIN THROMBOSIS;

ANTICOAGULANTS; BANDAGES; DECISION MAKING; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PRACTICE GUIDELINES; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PUERPERAL DISORDERS; RISK ASSESSMENT; RISK FACTORS; VENOUS THROMBOSIS;

EID: 33646688659     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Lindqvist P, Dahlbäck B, Marsál K. Thrombotic risk during pregnancy: a population study. Obstet Gynecol 1999;94(4):595-9.
2. May A. The confidential enquiries into maternal deaths 1997-1999: what can we learn? Int J Obstet Anesth 2002;11(3):153-5.
3. Blodpropp - förebyggande, diagnostik och behandling av venös tromboembolism. Stockholm: SBU - Statens beredning för medicinsk utvärdering; 2002.
4. Socialstyrelsens riktlinjer för vård av blodpropp/ venös tromboembolism. Stockholm: Socialstyrelsen; 2004. Rapport nr 2004-102-3.
5. Hem-ARG. Arbets och referensgruppen för hemostasrubbningar. Hemostasrubbningar inom obstetrik och gynekologi. Stockholm: Svensk förening för obstetrik och gynekologi; 2004. SFOG-ARG rapport nr 49.
6. Lindqvist PG, Olofsson P, Dahlbäck B. Use of selective factor V Leiden screening in pregnancy to identify candidates for anticoagulants. Obstet Gynecol 2002;100(2):332-6.
7. Lindqvist PG, Kublikas M, Dahlbäck B. Individual risk assessment of thrombosis in pregnancy. Acta Obstet Gynecol Scand 2002; 81(5):412-6.
8. Lindqvist PG, Svensson PJ, Marsál K, Grennert L, Lutherkort M, Dahlbäck B. Activated protein C resistance (FV:Q506) and pregnancy. Thromb Haemost 1999;81:532-7.
9. Curvers J, Nienhuis SJ, Nap AW, Hamulyak K, Evers JL, Rosing J. Activated protein C resistance during in vitro fertilization treatment. Eur J Obstet Gynecol Reprod Biol 2001;95(2):222-4.
10. Bremme K, van Rooijen M, Yu A, Blombäck M. Accumulation of low molecular mass heparin during prophylactic treatment in pregnancy. Blood Coagul Fibrinolysis 2001;12(2):149-55.
11. Blombäck M, Bremme K, Hellgren M, Siegbahn A, Lindberg H. Thromboprophylaxis with low molecular mass heparin, ÔFragmin (dalteparin), during pregnancy - a longitudinal safety study. Blood Coagul Fibrinolysis 1998;9(1):1-9.
12. Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993;168(4):1265-70.
13. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):311S-37S.
14. Lindqvist PG, Dahlbäck B. Bleeding complications associated with low molecular weight heparin prophylaxis during pregnancy. Thromb Haemost 2000;84:140-1.
15. Franchini M. Heparin-induced thrombocytopenia: an update. Thromb J 2005;3:14